tirzepatide weight loss medication for - Dual GIP/GLP-1 Guide FDA approves new version of

The weight loss curve typically follows a pattern: rapid initial loss in the first 8 weeks, steady continued loss through month 6, and stabilization by months 9 to 12 if diet and activity remain consistent

Food and Drug Administration (FDA) on December 5, 2017, for treating type 2 diabetes

The main difference between the two lies in the active ingredient

This comparison examines whether retatrutide's triple agonist mechanism offers clinically meaningful advantages over semaglutide's proven single-agonist approach, while acknowledging the fundamental asymmetry in evidence quality between a fully approved drug and an investigational compound

10.1093/ajcn/nqy310 [DOI] [PubMed] [Google Scholar] 101.Nor Hanipah Z, Punchai S, Birriel TJ, Lansang MC, Kashyap SR, Brethauer SA, et al